#SABCS25: BioNTech, BMS unwrap Phase 2 data for PD-L1xVEGF-A bispecific in breast cancernews2025-12-09T12:31:42+00:00December 9th, 2025|Endpoints News|
#ASH25: Eli Lilly’s Jaypirca makes first-line case, but ceiling may be cappednews2025-12-09T12:30:47+00:00December 9th, 2025|Endpoints News|
#ASH25: Novartis says its antibody ianalumab helps prolong control of rare blood disordernews2025-12-09T12:30:30+00:00December 9th, 2025|Endpoints News|
Eli Lilly will be ‘aggressive’ in spending GLP-1 money, top dealmaker Van Naarden saysnews2025-12-09T12:30:22+00:00December 9th, 2025|Endpoints News|
Pfizer to pay $150M upfront for small molecule GLP-1 from Fosun subsidiarynews2025-12-09T12:01:17+00:00December 9th, 2025|Endpoints News|
Cell and gene therapy benefits company Aradigm raises $20Mnews2025-12-09T12:00:26+00:00December 9th, 2025|Endpoints News|
Biosecure Act appears headed for final passage in defense billnews2025-12-08T20:17:06+00:00December 8th, 2025|Endpoints News|
FDA sets new, higher bar for CAR-T cancer treatments to prove superioritynews2025-12-08T19:57:56+00:00December 8th, 2025|Endpoints News|
#ASH25: Will a biotech’s pivot away from obesity let it compete with Novartis in leukemia?news2025-12-08T19:45:58+00:00December 8th, 2025|Endpoints News|
GSK walks away from remaining Ideaya programsnews2025-12-08T18:55:55+00:00December 8th, 2025|Endpoints News|
